Abstract:NOD-like receptor (NLR), family pyrin domain containing 3 (NLRP3) assembles a protein complex known as the NLRP3 inflammasome upon sensing certain pathogen products or sterile danger signals. Gain-of-function mutations such as the D301N substitution in NLRP3, which cause its constitutive activation (NLRP3CA) also results in inflammasome assembly. This inflammasome processes pro–interleukin-1 β (pro–IL-1β) and pro–IL-18 into bioactive IL-1β and IL-18, respectively, and cleaves gasdermin D (GSDMD). GSDMD amino-terminal fragments form plasma membrane pores that facilitate the secretion of IL-1β and IL-18 and lead to the inflammatory cell death pyroptosis. Accordingly, GSDMD inactivation results in negligible spontaneous inflammation in various experimental models such as in Nlrp3CA/+ mice lacking GSDMD (Nlrp3CA/+;Gsdmd−/− mice). Here, we found that Nlrp3CA/+;Gsdmd−/− mice, when challenged with LPS or TNF-α, still secreted IL-1β and IL-18, indicating inflammasome activation independent of GSDMD. Accordingly, Gsdmd−/− macrophages failed to secrete IL-1β and undergo pyroptosis when briefly exposed to NLRP3 inflammasome activators but released these cytokines when persistently activated. Sustained NLRP3 inflammasome induced caspase-8/-3 and GSDME cleavage and IL-1β maturation in vitro in Gsdmd−/− macrophages. Thus, a salvage inflammatory pathway involving caspase-8/-3–GSDME was activated after NLRP3 activation when the canonical NLRP3-GSDMD signaling was blocked. Consistent with genetic data, the active metabolite of FDA-approved disulfiram CuET, which inhibited GSDMD and GSDME cleavage in macrophages, reduced the severe inflammation and tissue damage that occurred in the Nlrp3CA/+ mice. Thus, NLRP3 inflammasome activation overwhelms the protection afforded by GSDMD deficiency, rewiring signaling cascades through mechanisms that include GSDME to propagate inflammation.

Biphasic JNK signaling reveals distinct MAP3K complexes licensing inflammasome formation and pyroptosis

Activation and Pharmacological Regulation of Inflammasomes

Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis

p38 MAPK Activity Is Required to Prevent Hyperactivation of NLRP3 Inflammasome

Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis

Molecular mechanism of pyroptosis and inflammasome activation

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

NLRP3 Phosphorylation is an Essential Priming Event for Inflammasome Activation.

Activated MLKL functions as signal II of the NLRP3 inflammasome

Post-translational control of NLRP3 inflammasome signaling

Consecutive palmitoylation and phosphorylation orchestrates NLRP3 membrane trafficking and inflammasome activation

K+ regulates Ca2+ to drive inflammasome signaling: dynamic visualization of ion flux in live cells

Initiation and perpetuation of NLRP3 inflammasome activation and assembly

NLRP3 Inflammasome Activation Triggers Gasdermin D–independent Inflammation

The two pore potassium channel THIK-1 regulates NLRP3 inflammasome activation

Optogenetically controlled inflammasome activation demonstrates two phases of cell swelling during pyroptosis

Inflammasome activation: from molecular mechanisms to autoinflammation

AKT Controls NLRP3 Inflammasome Activation by Inducing DDX3X Phosphorylation

GSK3β mediates the spatiotemporal dynamics of NLRP3 inflammasome activation

IKKβ primes inflammasome formation by recruiting NLRP3 to the trans-Golgi network

Inflammasomes as therapeutic targets in human diseases